Penny Tom Sells 38,806 Shares of Equillium, Inc. (NASDAQ:EQ) Stock

Equillium, Inc. (NASDAQ:EQ) insider Penny Tom sold 38,806 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $0.85, for a total value of $32,985.10. Following the completion of the transaction, the insider now directly owns 10,051 shares of the company’s stock, valued at approximately $8,543.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Equillium Stock Down 0.6 %

Shares of NASDAQ EQ opened at $0.85 on Thursday. The stock’s 50 day moving average price is $0.86 and its two-hundred day moving average price is $1.33. Equillium, Inc. has a 52-week low of $0.45 and a 52-week high of $3.25. The stock has a market capitalization of $29.97 million, a P/E ratio of -2.36 and a beta of 1.84.

Equillium (NASDAQ:EQ) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.16. Equillium had a negative return on equity of 36.88% and a negative net margin of 19.51%. The business had revenue of $13.85 million for the quarter, compared to analyst estimates of $8.15 million. On average, analysts anticipate that Equillium, Inc. will post -0.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Equillium in a research note on Monday, August 19th.

Institutional Trading of Equillium

A number of institutional investors and hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC bought a new position in shares of Equillium during the first quarter valued at approximately $249,000. Renaissance Technologies LLC grew its stake in Equillium by 43.6% during the 2nd quarter. Renaissance Technologies LLC now owns 300,400 shares of the company’s stock worth $208,000 after buying an additional 91,200 shares during the last quarter. Finally, Decheng Capital LLC bought a new position in Equillium during the 4th quarter worth $3,215,000. 27.05% of the stock is owned by institutional investors and hedge funds.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.